Prevention of Vertical Transmission of HIV: Strategies, Successes, and Failures
In this presentation, I would like to review what is working and what is apparently not working as tools to combat Mother-to-Child Transmission (MTCT) of HIV. With only 10% of the world population, Africa has more than 60% of the world’s people living with HIV and more than 90% of children with the virus are living in Sub Saharan Africa. It would take 8 years in the United States to reach the number of infants and children infected with HIV each day in developing countries.
KeywordsPlacebo Europe Palmitate Zidovudine Retinol
Unable to display preview. Download preview PDF.
- 1.Simonon A, Lepage P, Karita E, et al. An assessment of the timing of mother-to-child tranmission of human immunodeficiency virus type 1 by means of polymerase chain reaction. J Acquir Immune Def Syndr 1994; 7: 952–7.Google Scholar
- 3.Leroy V, Newell ML, Dabis F, Peckham C, Van de Perre P, Bulterys M, Kind C, Simonds RJ, Wiktor S, Msellati P, for the Ghent International Working Group on Mother-to-Child Transmission of HIV. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet 1998; 352: 597–600.PubMedCrossRefGoogle Scholar
- 7.Nduati R. Clinical studies of breast versus formula feeding. Second Conference on Global Strategies for the Prevention of HIV Transmission from Mother to Child, Montreal, Canada, septembre 1999. Presentation # 047.Google Scholar
- 9.Semba RD, Kumwenda N, Hoover DR, Taha TE, Quinn TC, Mtimavalye L, Biggar RI, Broadhead R, Miotti PG, Sokoll LJ, van der Hoeven L, Chiphangwi JD. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180: 93–8.PubMedCrossRefGoogle Scholar
- 12.Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. Six months efficacy, tolerance and acceptability of a short regimen of oral zidovudine in reducing vertical transmission of HIV in breast-fed children. A double blind placebo controlled multicentre trial, ANRSO49a, Côte d’Ivoire and Burkina Faso. Lancet 1999;353:786–92.PubMedCrossRefGoogle Scholar
- 14.Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795–802.PubMedGoogle Scholar
- 17.Wiktor S.Z., Leroy V., Ekpini E.R., et al. 24-month efficacy of short-course maternal zidovudine for the prevention of mother-to-child HIV-1 transmission in a breast feeding population. A pooled analysis of two randomized clinical trials in West Africa. 13thInternational AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstract TuOrB354.Google Scholar
- 18.Gray G. for the PETRA Trial Management Committee. The Petra study: early and late efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1. 13th International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstract LbOrS.Google Scholar
- 20.Beker-Pergola G., Guay L., Mmiro F., et al. Selection of the K103N Nevirapine resistance mutation in Ugandan women receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-006). 7thConference on Retroviruses and Opportunistic Infections, San Francisco, Jan 30-Feb 2 2000.Google Scholar
- 21.Jackson J.B., Mracna M., Guay L., et al. Selection of Nevirapine (NVP) resistance mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET012). 13th International AIDS Conference, Durban, South Africa, 9–14 July 2000.Google Scholar